Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice.

Aine McKillop, BM Moran, YHA Abdel-Wahab, NM Gormley, Peter Flatt

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

AIMS/HYPOTHESIS: Abnormal cannabidiol (Abn-CBD) and AS-1269574 are potent selective agonists for GPR55 and GPR119, respectively. The present study evaluated the actions and ability of these small-molecule agonists to counteract experimental diabetes in mice.METHODS: Diabetes was induced in NIH Swiss mice by five consecutive daily intraperitoneal injections of 40 mg/(kg body weight) streptozotocin. Diabetic mice received daily oral administration of Abn-CBD or AS-1269574 (0.1 μmol/kg) or saline vehicle (0.9% wt/vol. NaCl) over 28 days. Body weight, food intake, fluid intake, plasma glucose, insulin, glucose tolerance, insulin release, lipid profile and pancreatic morphology were examined. Mechanism of action of agonists was assessed in acute studies using incretin-receptor-knockout mice.RESULTS: Abn-CBD and AS-1269574 decreased plasma glucose (20-26%, p <0.05) and increased circulating insulin (47-48%, p <0.05) by 10-28 days, compared with saline-treated diabetic controls. Food intake and polydipsia were reduced by both agonists (21-23%, p <0.05 and 33-35%, p <0.01, respectively). After 28 days of treatment, plasma glucagon concentrations were reduced (p <0.01) and glucose tolerance was enhanced by 19-44% by Abn-CBD (p <0.05 or p <0.001) and AS-1269574 (p <0.05 to p <0.001). Plasma insulin responses were improved (p <0.01) and insulin resistance was decreased (p <0.05 or p <0.01) in both Abn-CBD- and AS-1269574-treated groups. Triacylglycerols were decreased by 19% with Abn-CBD (p <0.05) and 32% with AS-1269574 (p <0.01) while total cholesterol was reduced by 17% (p <0.01) and 15% (p <0.05), respectively. Both agonists enhanced beta cell proliferation (p <0.001) although islet area was unchanged. Acute studies in Gipr- and Glp1r-knockout mice revealed an important role for the glucagon-like peptide 1 (GLP-1) receptor in the actions of both agonists, with the glucose-lowering effects of Abn-CBD also partly mediated through the glucose-dependent insulinotropic peptide (GIP) receptor.CONCLUSIONS/INTERPRETATION: These data highlight the potential for fatty acid G-protein-coupled receptor-based therapies as novel insulinotropic and glucose-lowering agents acting partly through the activation of incretin receptors.
LanguageEnglish
Pages2674-2685
JournalDiabetologia
Volume59
Issue number12
Early online date27 Sep 2016
DOIs
Publication statusE-pub ahead of print - 27 Sep 2016

Fingerprint

Incretins
Streptozocin
Knockout Mice
Glucose
Insulin
Eating
Body Weight
Gastric Inhibitory Polypeptide
Polydipsia
Peptide Receptors
G-Protein-Coupled Receptors
4-(3-3,4-p-menthadien-(1,8)-yl)olivetol
Intraperitoneal Injections
Glucagon
Oral Administration
Insulin Resistance
2-(2-(4-bromophenyl)-6-methylpyrimidin-4-yl)aminoethanol
Triglycerides
Fatty Acids
Cholesterol

Keywords

  • Beta cell regeneration
  • Diabetes
  • Fatty acid agonists
  • G-protein-coupled receptors
  • Glucose homeostasis
  • Insulin secretion
  • Multiple low-dose streptozotocin

Cite this

@article{2e942405b0414a9d83cefb9385e96905,
title = "Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice.",
abstract = "AIMS/HYPOTHESIS: Abnormal cannabidiol (Abn-CBD) and AS-1269574 are potent selective agonists for GPR55 and GPR119, respectively. The present study evaluated the actions and ability of these small-molecule agonists to counteract experimental diabetes in mice.METHODS: Diabetes was induced in NIH Swiss mice by five consecutive daily intraperitoneal injections of 40 mg/(kg body weight) streptozotocin. Diabetic mice received daily oral administration of Abn-CBD or AS-1269574 (0.1 μmol/kg) or saline vehicle (0.9{\%} wt/vol. NaCl) over 28 days. Body weight, food intake, fluid intake, plasma glucose, insulin, glucose tolerance, insulin release, lipid profile and pancreatic morphology were examined. Mechanism of action of agonists was assessed in acute studies using incretin-receptor-knockout mice.RESULTS: Abn-CBD and AS-1269574 decreased plasma glucose (20-26{\%}, p <0.05) and increased circulating insulin (47-48{\%}, p <0.05) by 10-28 days, compared with saline-treated diabetic controls. Food intake and polydipsia were reduced by both agonists (21-23{\%}, p <0.05 and 33-35{\%}, p <0.01, respectively). After 28 days of treatment, plasma glucagon concentrations were reduced (p <0.01) and glucose tolerance was enhanced by 19-44{\%} by Abn-CBD (p <0.05 or p <0.001) and AS-1269574 (p <0.05 to p <0.001). Plasma insulin responses were improved (p <0.01) and insulin resistance was decreased (p <0.05 or p <0.01) in both Abn-CBD- and AS-1269574-treated groups. Triacylglycerols were decreased by 19{\%} with Abn-CBD (p <0.05) and 32{\%} with AS-1269574 (p <0.01) while total cholesterol was reduced by 17{\%} (p <0.01) and 15{\%} (p <0.05), respectively. Both agonists enhanced beta cell proliferation (p <0.001) although islet area was unchanged. Acute studies in Gipr- and Glp1r-knockout mice revealed an important role for the glucagon-like peptide 1 (GLP-1) receptor in the actions of both agonists, with the glucose-lowering effects of Abn-CBD also partly mediated through the glucose-dependent insulinotropic peptide (GIP) receptor.CONCLUSIONS/INTERPRETATION: These data highlight the potential for fatty acid G-protein-coupled receptor-based therapies as novel insulinotropic and glucose-lowering agents acting partly through the activation of incretin receptors.",
keywords = "Beta cell regeneration, Diabetes, Fatty acid agonists, G-protein-coupled receptors, Glucose homeostasis, Insulin secretion, Multiple low-dose streptozotocin",
author = "Aine McKillop and BM Moran and YHA Abdel-Wahab and NM Gormley and Peter Flatt",
year = "2016",
month = "9",
day = "27",
doi = "10.1007/s00125-016-4108-z",
language = "English",
volume = "59",
pages = "2674--2685",
journal = "Diabetologia",
issn = "0012-186X",
number = "12",

}

TY - JOUR

T1 - Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice.

AU - McKillop, Aine

AU - Moran, BM

AU - Abdel-Wahab, YHA

AU - Gormley, NM

AU - Flatt, Peter

PY - 2016/9/27

Y1 - 2016/9/27

N2 - AIMS/HYPOTHESIS: Abnormal cannabidiol (Abn-CBD) and AS-1269574 are potent selective agonists for GPR55 and GPR119, respectively. The present study evaluated the actions and ability of these small-molecule agonists to counteract experimental diabetes in mice.METHODS: Diabetes was induced in NIH Swiss mice by five consecutive daily intraperitoneal injections of 40 mg/(kg body weight) streptozotocin. Diabetic mice received daily oral administration of Abn-CBD or AS-1269574 (0.1 μmol/kg) or saline vehicle (0.9% wt/vol. NaCl) over 28 days. Body weight, food intake, fluid intake, plasma glucose, insulin, glucose tolerance, insulin release, lipid profile and pancreatic morphology were examined. Mechanism of action of agonists was assessed in acute studies using incretin-receptor-knockout mice.RESULTS: Abn-CBD and AS-1269574 decreased plasma glucose (20-26%, p <0.05) and increased circulating insulin (47-48%, p <0.05) by 10-28 days, compared with saline-treated diabetic controls. Food intake and polydipsia were reduced by both agonists (21-23%, p <0.05 and 33-35%, p <0.01, respectively). After 28 days of treatment, plasma glucagon concentrations were reduced (p <0.01) and glucose tolerance was enhanced by 19-44% by Abn-CBD (p <0.05 or p <0.001) and AS-1269574 (p <0.05 to p <0.001). Plasma insulin responses were improved (p <0.01) and insulin resistance was decreased (p <0.05 or p <0.01) in both Abn-CBD- and AS-1269574-treated groups. Triacylglycerols were decreased by 19% with Abn-CBD (p <0.05) and 32% with AS-1269574 (p <0.01) while total cholesterol was reduced by 17% (p <0.01) and 15% (p <0.05), respectively. Both agonists enhanced beta cell proliferation (p <0.001) although islet area was unchanged. Acute studies in Gipr- and Glp1r-knockout mice revealed an important role for the glucagon-like peptide 1 (GLP-1) receptor in the actions of both agonists, with the glucose-lowering effects of Abn-CBD also partly mediated through the glucose-dependent insulinotropic peptide (GIP) receptor.CONCLUSIONS/INTERPRETATION: These data highlight the potential for fatty acid G-protein-coupled receptor-based therapies as novel insulinotropic and glucose-lowering agents acting partly through the activation of incretin receptors.

AB - AIMS/HYPOTHESIS: Abnormal cannabidiol (Abn-CBD) and AS-1269574 are potent selective agonists for GPR55 and GPR119, respectively. The present study evaluated the actions and ability of these small-molecule agonists to counteract experimental diabetes in mice.METHODS: Diabetes was induced in NIH Swiss mice by five consecutive daily intraperitoneal injections of 40 mg/(kg body weight) streptozotocin. Diabetic mice received daily oral administration of Abn-CBD or AS-1269574 (0.1 μmol/kg) or saline vehicle (0.9% wt/vol. NaCl) over 28 days. Body weight, food intake, fluid intake, plasma glucose, insulin, glucose tolerance, insulin release, lipid profile and pancreatic morphology were examined. Mechanism of action of agonists was assessed in acute studies using incretin-receptor-knockout mice.RESULTS: Abn-CBD and AS-1269574 decreased plasma glucose (20-26%, p <0.05) and increased circulating insulin (47-48%, p <0.05) by 10-28 days, compared with saline-treated diabetic controls. Food intake and polydipsia were reduced by both agonists (21-23%, p <0.05 and 33-35%, p <0.01, respectively). After 28 days of treatment, plasma glucagon concentrations were reduced (p <0.01) and glucose tolerance was enhanced by 19-44% by Abn-CBD (p <0.05 or p <0.001) and AS-1269574 (p <0.05 to p <0.001). Plasma insulin responses were improved (p <0.01) and insulin resistance was decreased (p <0.05 or p <0.01) in both Abn-CBD- and AS-1269574-treated groups. Triacylglycerols were decreased by 19% with Abn-CBD (p <0.05) and 32% with AS-1269574 (p <0.01) while total cholesterol was reduced by 17% (p <0.01) and 15% (p <0.05), respectively. Both agonists enhanced beta cell proliferation (p <0.001) although islet area was unchanged. Acute studies in Gipr- and Glp1r-knockout mice revealed an important role for the glucagon-like peptide 1 (GLP-1) receptor in the actions of both agonists, with the glucose-lowering effects of Abn-CBD also partly mediated through the glucose-dependent insulinotropic peptide (GIP) receptor.CONCLUSIONS/INTERPRETATION: These data highlight the potential for fatty acid G-protein-coupled receptor-based therapies as novel insulinotropic and glucose-lowering agents acting partly through the activation of incretin receptors.

KW - Beta cell regeneration

KW - Diabetes

KW - Fatty acid agonists

KW - G-protein-coupled receptors

KW - Glucose homeostasis

KW - Insulin secretion

KW - Multiple low-dose streptozotocin

U2 - 10.1007/s00125-016-4108-z

DO - 10.1007/s00125-016-4108-z

M3 - Article

VL - 59

SP - 2674

EP - 2685

JO - Diabetologia

T2 - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 12

ER -